COGT
USDCogent Biosciences Inc. Common Stock
Precio en Tiempo Real
Gráfico de Precios
Métricas Clave
Métricas de Mercado
Apertura
$15.240
Máximo
$15.870
Mínimo
$13.980
Volumen
0.44M
Fundamentos de la Empresa
Capitalización de Mercado
2.0B
Industria
Biotecnología
País
United States
Estadísticas de Negociación
Volumen Promedio
1.89M
Bolsa
NMS
Moneda
USD
Rango de 52 Semanas
Noticias Relacionadas
HC Wainwright & Co. Reiterates Buy on Cogent Biosciences, Maintains $21 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Cogent Biosciences with a Buy and maintains $21 price target.
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2025 Financial Results
Phase 3 PEAK results in 2nd-line GIST patients expected in November; pivotal APEX results in AdvSM patients expected in December Breakthrough Therapy Designation granted for bezuclastinib; New Drug Application (NDA)
Cogent Biosciences Announces Multiple Presentations at the 67th Annual American Society of Hematology (ASH) Meeting
SUMMIT data for bezuclastinib in NonAdvSM selected for two oral presentations which will describe its best-in-class potential Novel JAK2 V617F mutant-selective inhibitor announced as Cogent's newest preclinical program;
Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
WALTHAM, Mass. and BOULDER, Colo., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today
JP Morgan Maintains Overweight on Cogent Biosciences, Raises Price Target to $44
JP Morgan analyst Anupam Rama maintains Cogent Biosciences with a Overweight and raises the price target from $30 to $44.
Acciones Relacionadas
Mantente Actualizado
Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.